What We're Reading: Page 211
Industry reads hand-picked by our editors
Aug 19, 2019
-
The New York Times
A Nun, a Doctor and a Lawyer — and Deep Regret Over the Nation's Handling of Opioids
-
Reuters
Novartis executive sold shares before drug data manipulation made public
-
Regulatory Focus
EMA and FDA Historically Agree on Just About Every New Drug Approval, But Is That Slowly Changing?
Aug 16, 2019
Aug 15, 2019
-
STAT
As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market
-
Vantage
Biopharma's biggest sellers – the oldies that just keep giving
-
Bloomberg
Investors Cash In on Ebola Bonds That Haven't Paid Out
-
LifeSciVC
The Creation Of Biotech Startups: Evolution Not Revolution
Aug 14, 2019
-
The New York TImes
Screen All Adult Patients for Drug Abuse, National Panel Urges
-
Bloomberg
Trump's Canada Drug Import Plan Can't Happen Without Big Pharma
-
Boston Business Journal
After Landos' $60M round, Xontogeny, accelerator launched by former Sarepta CEO Chris Garabedian, preps five new biotechs
Aug 13, 2019
-
The Wall Street Journal
DNA Data Shared in Ways Patients May Find Surprising
-
Axios
Surprise bills are everywhere
-
FierceHealthcare
Trump administration announces departure of drug pricing adviser John O'Brien
Aug 12, 2019
-
The Wall Street Journal
Drug Shortage Leaves Patients Without Immune-Disorder Treatment
-
Vantage
Autolus slams on the brakes in its Car
-
MIT Technology Review
Don’t change your DNA at home, says America’s first CRISPR law
-
STAT
Biotech faces a crisis in credibility fueled by boom-era hubris
Aug 09, 2019
-
The Boston Globe
The world’s most expensive medicine could save toddlers’ lives. But getting it is complicated
-
Bloomberg
Better birth control exists, but big pharma isn't interested
-
The San Diego Union-Tribune
Star scientist leaves Scripps Research under mysterious circumstances
-
Kaiser Health News
Where tourism brings pricey health care, locals fight back
Previous
